2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Chicago, Illinois, US 31 May 2024 - 04 June 2024
ECHELON-3: Brentuximab vedotin ticks another box on the lymphoma treatment board
A triplet regimen comprising the anti-CD30 antibody-drug conjugate (ADC) brentuximab vedotin (BV) plus lenalidomide and rituximab (R2) inches its way into the R/R DLBCL* treatment path in the prespecified interim analysis of the ECHELON-3 trial, further reinforcing the role of BV in lymphoma treatment.
KRYSTAL-12 boosts adagrasib as 2L Tx alternative for KRASG12C-mutated NSCLC
Findings from the phase III KRYSTAL-12 trial underpin the treatment potential of adagrasib for previously treated metastatic non-small cell lung cancer (NSCLC) harbouring a KRASG12C mutation.
Longest ever PFS in advanced NSCLC CROWNs lorlatinib’s 5-year data
After 5 years of follow-up, median progression-free survival (PFS) has still not been reached in patients with advanced non-small-cell lung cancer (NSCLC) treated with lorlatinib in the phase III CROWN study, corresponding to the longest PFS ever reported with any single-agent molecular targeted treatment in advanced NSCLC and across all metastatic solid tumours.
Subcutaneous amivantamab compares favourably with intravenous dosing in EGFR-mutant NSCLC
In previously treated patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC), subcutaneous (SC) amivantamab combined with lazertinib shows noninferior pharmacokinetic and efficacy profiles compared with the approved intravenous (IV) formulation of amivantamab, according to the phase III PALOMA-3 trial.
Consolidation durvalumab poised to become ‘new standard’ for limited-stage SCLC
Consolidation treatment with the PD-L1 antibody durvalumab following concurrent chemoradiotherapy significantly prolonged overall (OS) and progression-free survival (PFS) in patients with limited-stage small-cell lung cancer (SCLC), as shown in the interim analysis of the phase III ADRIATIC trial.
